Dexcom to add 2 board directors with activist investor Elliott

CEO Jake Leach also discussed the company’s plans for its G8 glucose sensor, dual-analyte sensing and Medicare coverage at an investor day.

Elliott strikes Dexcom board settlement after taking stake

Activist investor Elliott Investment Management has taken a stake in medical device firm Dexcom Inc. and struck a settlement ...
The Motley Fool

DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?

DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's ...
FierceBiotech

Dexcom receives FDA warning letter over CGM manufacturing issues

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. In a filing with the SEC, ...
Medscape

Dexcom Issues Recall for G7, ONE+ Apps for Software Issues

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Barron's

DexCom Stock Plunges 40% After Earnings. GLP-1s Weren’t the Problem.

DexCom reported a sales miss in the second quarter. (Courtesy DexCom) Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance, and grim news ...

DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%

Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...